Fundraising Fox

Spyre Therapeutics

NASDAQ: SYRE

2 known investors

Spyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.

BiotechHealthtechMedical Devices

Investors · 2

Access BiotechnologyNew York City
Aisling CapitalNew York

Competitors · 1

by search overlap
Sarepta Therapeutics43 shared keywordsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.

Companies competing with Spyre Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Spyre Therapeutics stock hits 52-week high at 108.16 USD By Investing.cominvesting.com · Aug 2026Spyre Therapeutics launches combination therapy trial for hidradenitis suppurativa By Investing.comca.investing.com · Aug 2026Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - BioSpacebiospace.com · Aug 2026Spyre Therapeutics (SYRE) Is Up 10.5% After Completing SKYWAY Enrollment and Expanding SPY003 Licensing Field - Simply Wall St Newssimplywall.st · Jun 2026Spyre Therapeutics Raises $463 Million to Fund IBD Clinical Programsharianbasis.co · Apr 2026Spyre Therapeutics Raises Capital Through Completed Stock Offering - TipRanks.comtipranks.com · Apr 2026

Frequently asked questions

What does Spyre Therapeutics do?
Spyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
Who are Spyre Therapeutics's investors?
Spyre Therapeutics's investors include Access Biotechnology, Aisling Capital.